ИНФЕКЦИЯЛЫҚ ПЕРИТОНИТТІ ЕМДЕУДЕГІ ЗАМАНАУИ ТИІМДІ ӘДІСТІ БАҒАЛАУ

Feline infectious peritonitis (FIP) is a severe and potentially fatal disease in domestic cats that remains challenging to diagnose and treat. The aim of this study was to evaluate the diagnostic indicators of FIP and assess the therapeutic efficacy of molnupiravir, both alone and in combination with hyperimmune serum, in cats with confirmed FIP. The study was conducted in the veterinary clinic in Astana, Kazakhstan, during 2025–2026. Ten cats aged 6 months to 6 years of different breeds diagnosed with FIP were included in the study. Clinical examination, hematological and biochemical blood analyses, radiography, and ultrasonography were performed. Ultrasonographic examination was conducted using the SonoScape S20 ultrasound diagnostic system, while biochemical parameters were determined using the SMT-120V automatic biochemical analyzer. The animals were divided into two treatment groups: molnupiravir monotherapy and molnupiravir combined with hyperimmune serum. The effusive form of FIP was the most frequently observed clinical form, accounting for 60% of cases. The predominant clinical signs included depression and stress (80%), pale mucous membranes (80%), fever ≥39.5°C (70%), dehydration ≥5% (70%), abdominal pain or spasms (60%), and abdominal enlargement (60%). Biochemical analysis before treatment revealed hyperproteinemia and hyperglobulinemia accompanied by hypoalbuminemia and a decreased albumin-to-globulin (A/G) ratio. By day 35 of treatment, most hematological and biochemical parameters had approached physiological reference values, with a marked increase in the A/G ratio. The combination of clinical signs and the A/G ratio demonstrated a diagnostic accuracy of 75%, compared with 40% for ultrasonography alone. A 100% recovery rate was observed in both treatment groups. Clinical recovery was achieved within 33–35 days in cats receiving molnupiravir alone and within 29–30 days in cats receiving molnupiravir combined with hyperimmune serum. These findings indicate that molnupiravir may represent a promising therapeutic option for cats with FIP, while its combination with hyperimmune serum may contribute to a shorter clinical recovery period.